• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Acceleron Pharma

edit

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Recent Milestones

edit

• 
  Acceleron Pharma received $30M in Series F funding. (12/23/11)
  Posted 12/23/11 at 6:10pm via finsmes.com
• 
  Acceleron Pharma — Acceleron Pharma Extends Runway Through $242M Celgene Alliance (8/3/11)
  Posted 8/3/11 at 8:06pm via dowjones.com
• 
  Acceleron Pharma received $1.5M in Grant funding. (1/6/11)
  Posted 1/11/11 at 12:41am via masshightech.com
• 
  Acceleron Pharma — has appointed Kevin McLaughlin as senior vice president and chief financial officer (11/29/10)
  Posted 11/29/10 at 8:34am via masshightech.com
• 
  Acceleron Pharma — Acceleron Pharma, Shire Form $498M Drug Development Alliance (9/10/10)
  Posted 9/13/10 at 1:15am via dowjones.com
• 
  Acceleron Pharma — Acceleron signs development deal with Shire (9/9/10)
  Posted 9/9/10 at 6:58am via masshightech.com
• 
  Acceleron Pharma received $8.4M in Venture Round funding. (6/22/10)
  Posted 7/7/10 at 1:59am via masshightech.com
• 
  Acceleron Pharma received $11M in Venture Round funding. (12/15/09)
  Posted 12/15/09 at 5:46pm via masshightech.com
• 
  Acceleron Pharma received $31M in Series C funding. (10/1/07)
  Posted 12/15/09 at 10:15pm via masshightech.com
• 
  Acceleron Pharma received $30M in Series B funding. (8/2/06)
  Posted 4/20/10 at 11:05pm via acceleronpharma.com
• 
  Acceleron Pharma added John Knopf as CEO, Founder.
  Posted 12/15/09 at 5:46pm
• 
  Acceleron Pharma added Anthony Evnin as Director.
  Posted 12/15/09 at 5:46pm
• 
  Acceleron Pharma added Jean George as Director.
  Posted 12/15/09 at 5:46pm
• 
  Acceleron Pharma added Terry McGuire as Director.
  Posted 12/15/09 at 5:49pm
• 
  Acceleron Pharma added Ed Kania as Director.
  Posted 12/15/09 at 5:50pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/16/09

Sources

1. Acceleron Pharma Closes $30M Series B Financing (acceleronpharma.com) [edit]
2. Acceleron to grow staff, manufacturing in Cambridge (masshightech.com) [edit]
3. Acceleron Pharma grows further with almost $11M financing (masshightech.com) [edit]
4. Acceleron Pharma pulls in $8.4M financing (masshightech.com) [edit]
5. Acceleron DMD drug target draws $1.5M grant (masshightech.com) [edit]
6. Acceleron Pharma Raises $30M in Funding (finsmes.com) [edit]
Acceleron signs lucrative development deal with Shire (masshightech.com) [edit]
Acceleron Pharma, Shire Form $498M Drug Development Alliance (fis.dowjones.com) [edit]
Qteros vet McLaughlin named Acceleron CFO (masshightech.com) [edit]
Acceleron Pharma Extends Runway Through $242M Celgene Alliance (fis.dowjones.com) [edit]